Clinical Trial Update: Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting that a cyclooxygenase-2 inhibitor reduced serum PSA levels in benign prostatic hyperplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• COX-2 inhibitor (unspecified)

Snippet

Sponsor: Buddhist Tzu Chi General Hospital | Conditions: Benign Prostatic Hyperplasia | Phase 2 | Status: COMPLETED | Results posted: 2014-06-30